

Proteomic Exploration of *Listeria monocytogenes* for the Purpose of Vaccine Designing Using a Reverse Vaccinology Approach

Shivani Srivastava¹ · Suraj Kumar Sharma¹ · Vivek Srivastava¹ · Ajay Kumar¹

Accepted: 22 October 2020 / Published online: 29 October 2020 © Springer Nature B.V. 2020

Abstract

Listeriosis is a major foodborne infection provoked by a bacterium known as *Listeria monocytogenes*. It is one of the predominant causes of death in pregnant women, infants, and immunocompromised persons. Despite such fatal effects, until now there is no proper medication or drug available for such a serious foodborne infection. One of the most promising ways to deal with this challenge is vaccination. This present study aims at the prediction of B cell epitopes for subunit vaccine designing against *Listeria monocytogenes* using a reverse vaccinology approach. Among screened out 299 epitopes of strain F2365 of *Listeria monocytogenes*, based on the VaxiJen score, the top 20 epitopes were selected. 3D modeling of epitopes and alleles was generated by PEPstrMOD and Swiss Model respectively. Molecular docking reveals 4 epitopes viz., MKFLFPLKL, CEETFGIRL, FLKIDPPIL, and VRHHGGGHK based on binding energy. All 4 epitopes were investigated for non-toxicity, binding affinity, and population coverage. After vigorous investigation, epitope FLKIDPPIL was anticipated as the best vaccine contender. The stability of the FLKIDPPIL-HLA DRB1_0101 complex was proved by performing the simulation. Here, predicted peptide through the *Insilico* approach may become a potential remedy against listeriosis, after the wet-lab approach and clinical trials.

Keywords Listeriosis · B cell epitopes · Docking · Simulation · Reverse vaccinology

Introduction

Changing food habits, advancement in technology regarding the preservation of food products for a longer time, and the ability of microorganisms to grow in adverse conditions are leading to the emergence of the foodborne infection, known as Listeriosis. The genus *Listeria* consists of seventeen species. Only the three hemolytic species viz., *Listeria monocytogenes*, *Listeria seeligeri*, and *Listeria ivanovii* are considered pathogens. Of these, *Listeria monocytogenes* is consistently pathogenic and is involved in foodborne outbreaks of listeriosis (Abdelhamed et al. 2019). Based on Gram-staining, *Listeria monocytogenes* comes under the category of Gram-positive. It shows extreme resistance in conditions like very high temperatures or very low temperatures. These bacteria have a rod-like shape and can form small chains (Sallami et al. 2006). Listeria monocytogenes mainly affects women who are pregnant, infants, elders above 65 years of age, and immunocompromised people (CDC 2019). Foodborne infection in humans occurs through the consumption of contaminated foods, particularly unpasteurized milk, soft cheeses, vegetables, and prepared meat products. Listeria monocytogenes show completely different behavior in comparison to all other pathogens that cause food contamination. It can multiply at low temperatures in contaminated food. It can be easily transmitted between pregnant women and her newborn either at the time of pregnancy or during delivery (WHO 2019). Pyrexia, cough, cold, headache, and body ache, etc. are the usual symptoms experienced by the patients (Department of Health 2017). Worldwide many countries where food production takes place in absence of proper and better microbiological vigilance and where the percentage of immunocompromised persons are immensely high, Listeria monocytogenes loomed as one of the dominant foodborne pathogens (Thomas et al. 2020). Thus, poor surveillance during the production process affects approximately 1600 people every year, and around 260 experience the afterlife (CDC 2019).

Ajay Kumar ajaymtech@gmail.com

¹ Department of Biotechnology, Faculty of Engineering and Technology, Rama University Uttar Pradesh, Kanpur 209217, India

Listeria monocytogenes consists of two genes viz., *chiA* and *chiB*. These two genes play an important role in virulence. A regulatory factor *hfq* plays a very important role in the formation of biofilm, colony formation, and virulence (Yao et al. 2018). The Zipper is the name of the mechanism through which *Listeria monocytogenes* get access to the host cell. In this process, ligands on the surface of bacteria communicate with receptors of the host cells. Internalin A and Internalin B are the ligands on the bacterial surface and E-cadherin and Met are the receptors on host cells with which bacterial ligands interact. This collaboration leads to the rearrangement of actin filaments and invasion of bacteria (Hamon et al. 2006). When Internalin B-Met interacts together, processes like ubiquitinylation and autophosphorylation takes place (Veiga and Cossart 2005).

In the year 2018, Australia had witnessed around 20 cases of listeriosis between January to April. This minor outbreak had faced around 7 deaths and a single spontaneous abortion (WHO 2018a, b). National Institute of Communicable diseases (NICD) has proclaimed 978 listeriosis cases between 2017 and 2018 from all provinces of South Africa, Gauteng, Western Cape, and KwaZulu- Natal were mainly hit by this fatal disease known as listeriosis. Around 78% of cases have been reported from the above-mentioned places of South Africa. Out of 674 affected people, 27 have faced death. All these data revealed about the threat of this bacteria and its effect on mankind and society. The percentage of infants that get affected during an outbreak is around 42% (WHO 2018a, b). Pregnant women can easily get infected with listeriosis through the placenta, still, the establishment of neurolisteriosis is completely occasional. Listeriosis infection in pregnant women is because of the alliance of the quashed immune system and the specificity of bacteria for the placenta (Charlier et al. 2017). Even after the birth of infants infected with bacteria Listeriosis monocytogenes endurance is possible only with the help of Extracorporeal membrane oxygenation (ECMO) (Lee et al. 2019). According to a report of WHO, in India miscarriages and other pregnancy-related disorders is mainly the result of foodborne infection known as listeriosis.

Listeriosis is still under-reported in many countries. The ability of *Listeria monocytogenes* to survive even in harsh conditions is one of the major threats regarding the outbreak of the disease. High fatality rate and frequent outbreaks demand the designing of a vaccine against *Listeria monocytogenes*, by using the immunoinformatics approach. This study is mainly based on the anticipation of B cell epitopes for the utility of vaccine designing against listeriosis. Previously, a study regarding computational identification and characterization of epitopes has been carried out in the case of the Zika virus, Nipah virus, and bacteria like *E. coli* (Sharma et al. 2020; Kaushik 2019; Khan et al. 2019). Considering this approach in this research work, all proteins except hypothetical, putative, and non-structural were retrieved from the UniProtKB database. A potential epitope must not possess any allergic property; therefore, first and foremost allergenicity was checked by using the AlgPred server. NETMHCII 2.3 and VaxiJen server was used to identify B cell epitopes that could bind to MHC II molecules with great stability. Only the top 20 epitopes were selected for further exploration. This selection was done based on the VaxiJen score. 3D modeling of both the epitopes and alleles was performed using PEPstrMOD and Swiss Model. Epitope—allele pair having low binding energy should be selected for the next sequential refining. To do this, molecular docking was performed using AutoDock Vina software. Next to check toxicity, binding affinity, and population coverage Toxin Pred, MHC Pred, and immune epitope database tools were used. The stability of the epitope-allele complex was substantiated by simulation studies. The strategy of the development of subunit vaccines has an upper hand in comparison to traditional vaccines. These next-generation vaccines are extremely specific in eliciting the immune system of the host, can be produced easily in large quantities, and at a comparatively moderate cost. Moreover, peptides consisting of epitopes can be manufactured, purified, and processed easily (Poland et al. 2011).

Methodology

Protein Sequence Retrieval

For computational identification and characterization of epitopes for the preparation of subunit vaccine designing, complete proteome analysis of Listeria monocytogenes F2365 strain (GenBank accession number AE017262.2) was performed using the UniProtKB database. In comparison to other serotype strains, Listeria monocytogenes strain F2365 belongs to the 4b serotype group and multiplicates more rapidly in monocytes or macrophages (Hasebe et al. 2017). Presence of a virulence factor viz. ListeriolysinS (LLS) in the F2365 strain accelerates infection in the intestine and other organs (Quereda et al. 2016). Listeria monocytogenes F2365 strain is a member of lineage I and comprises a factor known as Internalin B which plays a crucial role in nonpregnant infected animals (Quereda et al. 2018). All these remarkable features contribute to the pathogenicity of this strain and hence lead to its selection for the study. Excluding hypothetical, putative, and non-structural proteins total of 529 proteins were registered in the UniprotKB database, derived from the different research literature. All these sequences were saved in the FASTA format for further examination. The length of the genome of the F2365 strain is 3,021,822 bp, with GC content of 37.9% approximately (Briers et al. 2011).

Allergenic Protein Prediction

One of the most eminent features in epitope-based vaccine design is that the particular epitope must elicit an immune response only against the target pathogen. Taking this point into consideration, the screened epitope must be non-allergen and thus retrieved proteins were differentiated into allergens and non-allergens by using the AlgPred server (Saha and Raghava 2006) This server segregates non-allergens from allergens and -0.4 was selected as the cut-off value. Anticipation was done with high accuracy along with sensitivity and specificity of 88.87% and 81.86% respectively. Non-allergens were chosen for another characterization and exploration of antigenic sites for the utility of vaccine designing from the proteome of *Listeria monocytogenes*.

B cell Epitope Prediction

B cell epitopes are typical peptide remnants that bind to the immunoglobulin and thus it becomes immensely important to screen out such epitopes from complete proteome sequence. To accomplish this objective, NETMHCII 2.3 server was used (Jensen et al. 2018). By making use of artificial neural networks, this server predicts the binding of B cell epitopes with HLA alleles. In this study, three alleles viz. DRB1_0101, DRB1_0701, and DRB1_1301 and locus HLA-DR was chosen. The peptide length was taken at 9 with a threshold set to -99.9.

The potential B cell epitopes were subjected to the Vaxi-Jen server to select those candidates that can strongly bind with MHC II molecules (Doytchinova and Flower 2007). Only epitopes with a score greater than or equal to 1.1 can bind with MHC II molecules with extreme affinity and be selected. To further proceed with the reverse vaccinology approach, only the top 20 peptides or antigenic sites were chosen. This selection was based on the VaxiJen score.

Molecular Modeling of Epitopes and Human Leukocyte Antigen (HLA) Alleles

Following allergenicity and prediction of B cell epitopes, modeling of both epitopes and HLA alleles was performed. For the generation of the 3D structure of the selected epitopes, the PEPstrMOD server was used. It offers exclusive advantages to the users to predict the structures of peptides having natural residues, some modified residues, posttranslational modifications, etc. (Singh et al. 2015). In this research work, filtered epitopes were modeled and saved in the Protein Data Bank (PDB) format for the next sequential investigation. The first fully automated protein homology modeling server known as the Swiss model was used for modeling of HLA alleles (Waterhouse et al. 2018). The building of models using this server requires four sequential steps. These 4 steps comprise of template selection, its alignment with the target sequence, model building, and its evaluation. In this study 3D structures of three HLA alleles have been performed viz., DRB1_0101, DRB1_0701, and DRB1_1301.

Molecular Docking of Epitopes and HLA Alleles

To better understand the relationship between anticipated epitopes and their respective alleles, AutoDock Vina software was used to perform molecular docking. It helps us to interpret the synergy between antigenic sites and their corresponding alleles (Trott and Olson 2010). One of the prerequisites before performing docking is certain modifications both in ligand as well as the receptor, which was performed by AutoDock MGL tools. HLA alleles were selected as receptors viz., DRB1_0101, DRB1_0701, and DRB1_1301. 4AH2, 3C5J, and 6CQL are the crystal structure of these receptors and were retrieved from the Research Collaboratory for Structural Bioinformatics (RCSB) protein data bank. Molecules of water were removed from these receptors and polar hydrogen as well Kollman charges were added to the structure. After modification, the molecule was saved in pdbqt format. Changes were also performed in all 20 ligands and were saved in pdbgt files. All these alterations were performed by AutoDock MGL tools. To perform molecular docking in AutoDock Vina software, 40, 40, 40 were taken as grid box dimensions and energy was calculated at 0 Å. The docking result can be analyzed by a visualization tool called PyMol. 4 epitopes were selected for succeeding rounds of analysis based on negative binding energies where Low binding energy implies good stability.

Toxicity Prediction of the Epitopes

To evaluate the non-toxicity behavior of epitopes Toxin Pred server was used (Gupta et al. 2013). It is based on machine learning techniques and quantitative matrix scores. Along with toxicity prediction, calculation of physicochemical properties is one of the most notable features of this server.

Binding Affinity Prediction and Population Coverage Analysis

MHC Pred Server was used to vaticinate the binding affinity of epitopes with MHC II molecules. MHC Pred is composed of several models based on structures and its activity, a sturdy multivariate statistical method. Results with articulated by giving IC_{50} values (Guan et al. 2003). IC_{50} values less than 500 are considered to be good binders and were chosen for the next and last analysis. Because of the exceptionally heterogeneous behavior of HLA alleles, their frequency of expression varies greatly across the globe, and therefore Population coverage analysis becomes the utmost important step in computational vaccine designing. It was performed using the Immune Epitope Database (IEDB) Population Coverage analysis tool (Bui et al. 2006).

Molecular Dynamics (MD) and Simulation Study

It is extremely essential to understand the stability of the peptide- allele complex and to analyze that in this research work MD Web server was used (Hospital et al. 2012). Simulation of 10 ns with an output frequency of 500 steps was set to equilibrate the system. Coarse-grained Brownian dynamics were analyzed for trajectory and output was given in the terms of Root mean square deviation (RMSD) and B-factor values. Both RMSD and B-factor plots corroborate the stability of epitope- allele complex.

Results

With time, the world has acknowledged extreme advancement in medicine and technology thus combating some deadly diseases, but still, diseases like listeriosis were left unnoticed. Despite several outbreaks in different parts of the world, there is no legitimate treatment or drug or vaccine available for it. Therefore, it becomes extremely important to predict and characterize some potential vaccine contenders that can evoke a strong immune response and this study is one such step in this direction. Here we have used computational tools to predict B cell epitopes that can elicit an immune response. The first requirement in the reverse vaccinology approach of vaccine designing is to eliminate all non-allergic proteins from a complete proteome set of bacteria, Listeria monocytogenes. The AlgPred server was used to predict allergenicity of retrieved proteins, to get the most capable subunit vaccine candidate. A total of 529 protein sequences of Listeria monocytogenes F2365 strain was retrieved from the UniProtKB database (excluding hypothetical, putative, and non-structural proteins) and were saved in the FASTA format for further analysis. After examination by the AlgPred server, out of 529, a total of 172 proteins were proved to be non-allergens (Table 1). The result has been summarized in Table 1. Table 1 consists of protein ID, protein names, and scores of all non-allergens.

Non-allergic proteins were analyzed further by using NetMHC II 2.3 server. By selecting peptide lengths 9 and threshold value – 99.9. B cell epitopes were selected. These chosen epitopes were next investigated by the VaxiJen server and the cut-off value was 1.1 Å total of 299 epitopes were found to bind with MHC II molecules (Table 2). All 299 epitopes have a VaxiJen score of \geq 1.1 and can bind with MHC II molecules with great stability. Among these epitopes, the majority of epitopes were found to bind with DRB1_1301.

Based on the high VaxiJen score, among 299 epitopes, only the top 20 epitopes were selected for modeling. The generation of 3D structures of epitopes was performed by PEPstrMOD. 3D modeling of the HLA allele's viz. DRB1_0101, DRB1_0701, and, DRB1_1301 were performed by the Swiss model (Fig. 1). For the generation of tertiary structures of DRB1_0101, DRB1_0701 and, DRB1_1301 alleles, proteins having PDB ID 4AH2, 3C5J, and 6CQL were used as templates, respectively. All tertiary structures of HLA alleles were visualized by the PyMOL visualization tool. 3D models have been represented in Fig. 1.

AutoDock Vina software was used to perform molecular docking between 20 nonallergic and antigenic epitopes with their respective alleles. The lowest binding energy was obtained for epitope FLKIDPPIL-DRB1_0101 (- 7.3 kcal/ mol) and the highest binding energy was obtained for epitopes MKGQAGSKK-DRB1_1301 (- 5.1 kcal/mol). As low binding energies imply, high stability of the complex, therefore 4 epitopes based on low binding energy was selected viz., CEETFGIRL, MKFLFPLKL, FLKIDP-PIL, and VRHHGGGHK (Table 3). The stable complex of CEETFGIRL-3C5J shows the energy of -6.7 kcal/mol and 6 hydrogen bonds (Fig. 2) Complexes viz. MKFLFPLKL-4AH2 and FLKIDPPIL-4AH2 shows binding energy of - 6.9 kcal/mol and - 7.3 kcal/mol along with 2 and 6 hydrogen bonds respectively (Figs. 3 and 4). The energy of - 6.7 kcal/mol and 6 hydrogen bonds was shown by epitope VRHHGGGHK along with its receptor 6CQL (Fig. 5).

Most promising vaccine aspirants must not cause any kind of toxicity or vigorous reaction inside the host. So, checking of toxic nature of epitopes is notably important. This prominently important step was performed by Toxin Pred. It was found that all 4 selected epitopes were non-toxic (Table 4). All epitopes along with their result of toxicity analysis and physicochemical properties like hydrophobicity, hydrophilicity, and molecular weight were summarized in Table 4.

MHC Pred server was used to study the binding affinity of four non-allergic, non-toxic, and antigenic peptides with allele's viz., HLA DRB1_0101, HLA DRB1_0401, and HLA DRB1_0701. Binding affinity was depicted in terms of IC₅₀ value (Table 5). Epitopes showing IC₅₀ value less than 500 nM were considered to be good binders. Epitopes viz., CEETFGIRL and VRHHGGGHK were found to bind with HLA DRB1_0101 and HLA DRB1_0401, respectively. Both FLKIDPPIL and MKFLFPLKL were found to bind with HLA DRB1_0101 and HLA DRB1_0701.

Most eligible vaccine contenders must show satisfactorily population coverage in different parts of the world. Both the

S. no.	Protein ID	Score	AlgPred prediction
1	Q724L4	1.3656	Non-allergen
2	Q71WU4	1.9397	Non-allergen
3	Q71Z75	0.7278	Non-allergen
4	Q724J4	- 0.547	Non-allergen
5	Q71W17	- 0.551	Non-allergen
6	Q71Y34	- 0.54	Non-allergen
7	Q71XR2	0.4524	Non-allergen
8	Q71VT6	0.4088	Non-allergen
9	Q71ZE0	- 1.318	Non-allergen
10	Q71XX6	- 1.042	Non-allergen
11	Q71Y46	- 0.679	Non-allergen
12	Q71WT3	- 0.482	Non-allergen
13	Q71WP0	- 1.372	Non-allergen
14	Q720A5	- 0.44	Non-allergen
15	Q71WP7	- 0.675	Non-allergen
16	Q71WT2	- 0.574	Non-allergen
17	Q71ZH3	- 0.508	Non-allergen
18	Q720D7	- 1.554	Non-allergen
19	Q71VR6	- 1.317	Non-allergen
20	O720T3	- 0.947	Non-allergen
21	0722V6	- 0.505	Non-allergen
22	071YI4	- 0.578	Non-allergen
23	071WT9	- 0.64	Non-allergen
24	072011	- 1.004	Non-allergen
25	071ZD3	- 0.651	Non-allergen
26	071ZZ0	- 1.285	Non-allergen
27	071XV7	- 1.047	Non-allergen
28	071YD8	- 1.391	Non-allergen
29	Q71XG0	- 0.986	Non-allergen
30	0724M5	- 0.647	Non-allergen
31	0724E9	- 0.838	Non-allergen
32	071Y15	- 0.821	Non-allergen
33	0722Y8	-1.001	Non-allergen
34	Q72213 071XF3	- 0.951	Non-allergen
35	071VR5	- 0 589	Non-allergen
36	Q71WI0	- 0.766	Non-allergen
37	071737	- 0.698	Non-allergen
38	Q71XR3	- 1 167	Non-allergen
39	Q71/KG9	- 0.776	Non-allergen
40	Q72032	- 1.037	Non-allergen
41	Q71132	- 1.471	Non-allergen
42	Q71XV0	- 0.608	Non-allergen
42	Q724NI3	- 1.057	Non-allergen
45	072411	- 0.449	Non-allergen
44	072182	- 0.587	Non-allergen
45	Q72132	- 0.387	Non-allergen
-+0 17	Q/1AA2 071WU2	- 0.920	Non allergen
+/ /Q	Q/1WH2	- 0.3	Non allergen
40	Q/17Q8	- 0.948	Non allergen
49 50	Q/12D8	- 0.829	Non-allergen
50	Q/1139	- 1./20	INOn-allergen
51	Q/20E4	-0.977	Non-allergen

Table 1 (continued)

S. no.	Protein ID	Score	AlgPred prediction
52	Q71ZU1	- 0.488	Non-allergen
53	Q720A3	- 0.482	Non-allergen
54	Q720D3	- 0.466	Non-allergen
55	Q71YM4	- 0.874	Non-allergen
56	Q720A7	- 1.041	Non-allergen
57	Q724H7	- 0.885	Non-allergen
58	Q720J2	- 0.5	Non-allergen
59	Q71YJ0	- 1.126	Non-allergen
60	Q722Y2	- 0.645	Non-allergen
61	Q71XU1	- 0.474	Non-allergen
62	Q71WU5	- 1.035	Non-allergen
63	Q71YA9	- 1.006	Non-allergen
64	Q721B5	- 0.439	Non-allergen
65	Q71WN3	- 0.872	Non-allergen
66	0724F0	- 0.73	Non-allergen
67	071WP3	- 1.021	Non-allergen
68	071WF9	- 1.887	Non-allergen
69	0722W7	- 0.595	Non-allergen
70	Q71YH0	- 0.671	Non-allergen
71	071WB6	- 1.955	Non-allergen
72	071YB9	- 0.633	Non-allergen
73	071VR4	-0.492	Non-allergen
74	071W89	- 1.05	Non-allergen
75	071W91	- 0.849	Non-allergen
76	0721K3	- 0.808	Non-allergen
70	Q721R5	- 0 707	Non-allergen
78	071VH8	- 0.796	Non-allergen
78	071WG3	- 1.08	Non-allergen
80	0725C1	- 0.66	Non-allergen
81	071771	- 0.00	Non-allergen
82	071775	- 1.750	Non allergen
82 82	072221	- 0.399	Non allergen
84	Q722E1	- 0.432	Non allergen
04 95	Q720E1	- 0.419	Non-allergen
0J 96	Q724K0	- 0.41	Non-allergen
80	Q/1wF2	- 1.603	Non-allergen
87	Q724K2	- 0.421	Non-allergen
88	Q722 ¥9	- 0.81	Non-allergen
89	Q/IZA5	- 0.444	Non-allergen
90	Q/IVWI	- 0.761	Non-allergen
91	Q/1wF/	- 0.62	Non-allergen
92	Q/IZZ2	- 1.919	Non-allergen
93	Q/1W69	- 1.29	Non-allergen
94	Q7IWFI	- 1.529	Non-allergen
95	Q/IWE/	- 1.644	Non-allergen
96	Q71WU6	- 0.49	Non-allergen
97	Q71ZP6	- 0.605	Non-allergen
98	Q71WF3	- 2.172	Non-allergen
99	Q71WE9	- 1.315	Non-allergen
100	Q71WB7	- 2.462	Non-allergen
101	Q71WH0	- 1.831	Non-allergen
102	0724G4	-0.778	Non-allergen

Table 1 (continued)

S. no.	Protein ID	Score	AlgPred prediction
103	Q71WF8	- 1.611	Non-allergen
104	Q724G2	- 0.644	Non-allergen
105	Q71XE5	- 0.913	Non-allergen
106	Q71XX1	- 0.625	Non-allergen
107	Q71YK6	- 0.683	Non-allergen
108	Q71WE5	- 2.321	Non-allergen
109	Q71ZR7	- 0.454	Non-allergen
110	Q71WF6	- 1.29	Non-allergen
111	Q71WF5	- 1.581	Non-allergen
112	Q71WH1	- 2.223	Non-allergen
113	Q71WG5	- 1.192	Non-allergen
114	O725B8	- 2.188	Non-allergen
115	071WV5	- 1.028	Non-allergen
116	071WG0	- 1.557	Non-allergen
117	071WG2	- 1.87	Non-allergen
118	Q71WE8	- 0.989	Non-allergen
119	071YD4	- 2,112	Non-allergen
120	071YN5	-2.041	Non-allergen
1 21	071¥13	- 1.036	Non-allergen
121	072187	- 0.737	Non-allergen
122	071WX8	- 1.06	Non-allergen
123	Q71WE0	- 2 159	Non-allergen
124	Q71W10	- 2.139	Non allergen
125	072500	- 1.011	Non allergen
120	Q723C0	- 0.038	Non allergen
127	071768	- 0.327	Non-allergen
120	Q71Z08	- 0.898	Non-allergen
129	Q/1ZJ0	- 1.318	Non-allergen
130	Q/1XH4	- 1.281	Non-allergen
131	Q/IWLS	- 0.848	Non-allergen
132	Q720A8	- 0.628	Non-allergen
133	Q/21Y1	- 0.988	Non-allergen
134	Q71YM9	- 1.733	Non-allergen
135	Q71WG4	- 2.217	Non-allergen
136	Q71YN4	- 2.371	Non-allergen
137	Q71WH3	- 2.224	Non-allergen
138	Q71ZY7	- 0.968	Non-allergen
139	Q71XW7	- 1.979	Non-allergen
140	Q720A1	- 0.577	Non-allergen
141	Q723G3	- 2.038	Non-allergen
142	Q71WV3	- 0.925	Non-allergen
143	Q71ZJ5	- 0.952	Non-allergen
144	Q721N6	- 0.586	Non-allergen
145	Q71ZK1	- 1.532	Non-allergen
146	Q71ZD0	- 1.746	Non-allergen
147	Q71WF4	- 0.935	Non-allergen
148	Q71YL9	- 2.126	Non-allergen
149	Q71WG9	- 1.537	Non-allergen
150	Q71YK0	- 2.221	Non-allergen
151	Q71WI2	- 2.143	Non-allergen
152	Q71VQ6	- 1.957	Non-allergen
153	O724G8	- 1.5	Non-allergen

_	_	_	_	_

 Table 1 (continued)

S. no.	Protein ID	Score	AlgPred prediction
154	Q722D6	- 1.506	Non-allergen
155	Q71XL9	- 0.743	Non-allergen
156	Q720B5	- 0.934	Non-allergen
157	Q71XA1	- 1.344	Non-allergen
158	A6X137	- 0.435	Non-allergen
159	Q71Z99	- 0.409	Non-allergen
160	Q71YM0	- 1.017	Non-allergen
161	Q724P3	- 0.613	Non-allergen
162	Q71XW0	- 0.917	Non-allergen
163	Q720B7	- 0.621	Non-allergen
164	Q721A0	- 0.643	Non-allergen
165	Q71ZL4	- 0.912	Non-allergen
`166	Q721A5	- 0.545	Non-allergen
167	Q71YW0	- 0.48	Non-allergen
168	Q2N761	- 1.386	Non-allergen
169	L9WZX9	- 0.694	Non-allergen
170	A0A0X1KHF9	- 0.575	Non-allergen
171	Q1KT30	- 0.508	Non-allergen
172	Q1KT48	- 0.458	Non-allergen

epitope MKFLFPLKL and FLKIDPPIL shows population coverage of 28.63% worldwide (Fig. 6).

Epitope CEETFGIRL and VRHHGGGHK shows population coverage of 11.53% and 11.21% worldwide respectively (Figs. 7 and 8).

The final selection of best and most promiscuous vaccine bidders depends on two main factors, one is low binding energy and another one is high population coverage worldwide. Based on these two factors, epitope FLKIDPPIL was refined. To check the stability of complex FLKIDPPIL-4AH2, molecular dynamics simulation was performed by MD Web simulation. RMSD value of FLKIDPPIL-4AH2 was given in between 0.1 and 1.0 Å (Fig. 9) and B factor scores between 1 and 25 Å² (Fig. 10). Both RMSD values and B factor plot of complex viz., FLKIDPPIL-4AH2 confirm the stability of the epitope.

Discussion

Reverse vaccinology is known by different names like computational biology, immunoinformatics, and many more. It is a combination of immunological research as well as experimental and computational science. It includes computational tools and software to study the immune response of the host against various infectious diseases. Immunoinformatics helps us to understand antigen presentation in host cells, the behavior of the host during the infection cycle, and thus enriches the knowledge about the disease that affects the immune system and its control (Brusic and Petrovsky 2005). With the help of *Insilico* tools, antigenic regions can be mapped easily (Davies and Flower 2007). Previously, finding these antigenic regions are extremely costly and time-consuming methods like Nuclear Magnetic Resonance (NMR) were used. But today, computational vaccinology had made it possible to predict these antigenic regions in a short period and also with extreme accuracy (Potocnakova et al. 2016). In this exploration and investigation, the prediction of B cell epitopes has been performed by the authors for the designing of the vaccine against listeriosis by using a reverse vaccinology approach.

This research work started with the retrieval of a complete proteome sequence of Listeria monocytogenes F2365, from the UniProtKB database. Most promiscuous B cell epitopes must not show allergic properties. Therefore, to remove all allergic proteins from the investigation AlgPred server was used. A total of 529 proteins of the F2365 strain of Listeria monocytogenes have been proclaimed from the UniProtKB database. Out of 529 proteins, 172 have shown non-allergenicity. These 172 non-allergic proteins have been used to find out the best antigenic regions or peptides that can provoke great immune inflammation in the human body, by using NETMHCII 2.3 server. 299 epitopes have been identified by the VaxiJen server that could bind with MHC II molecules with great stability. Based on the VaxiJen score, only the top 20 B cell epitopes were selected for succeeding refining. 3D modeling of all 20 epitopes has been performed by PEPstrMOD and all these tertiary structures have been saved in PDB format. Tertiary structure modeling of alleles was generated with the help of HLA alleles were performed

Q71WU4 DRB1_1301 MNFRLKNMG 57.4 1.4634 Antigen Q71WU4 DRB1_1301 VAAMNFRLK 64.6 2.5495 Antigen Q71Z75 DRB1_1301 LSTKGKNRK 8.8 1.9105 Antigen DRB1_1301 VAARRSHRE 20.2 1.1808 Antigen DRB1_1301 VAARRSHR 23.5 1.4005 Antigen DRB1_1301 KVAARRSHR 23.5 1.4005 Antigen Q724J4 DRB1_0101 LHFLWNSNL 527.4 1.2681 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 MKGQAGSKK 49.4 2.2596 Antigen DRB1_1301 QARRANIRF 17.4 2.2999 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 KKLGARLER 60.8<	Table 2List of B cell epitopesas anticipated by NETMHCII2.3 server and the result ofVarilen analysis indicating	Protein ID	Allele	Peptide	Binding affin- ity [nM]	VaxiJen score	Antigen/ non- antigen
C F	antigenicity of epitopes	071WU4	DRB1 1301	MNERI KNMG	57.4	1 4634	Antigen
Q71Z75 DRB1_1301 LSTKGKNRK 8.8 1.9105 Antigen DRB1_1301 VAARRSHRE 20.2 1.1808 Antigen DRB1_1301 VAARRSHRE 20.2 1.1808 Antigen DRB1_1301 KVAARRSHR 23.5 1.4005 Antigen Q724J4 DRB1_0101 LHFLWNSNL 527.4 1.2681 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 IRLST 44.7 1.2681 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 KKLGARLER 60.8 1.1766 Antigen DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen DRB1_0101 FANIRPIQV 76 1.1402 Antigen DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen <td></td> <td>Q/1004</td> <td>DRB1_1301</td> <td>VAAMNERI K</td> <td>57.4 64.6</td> <td>2 5495</td> <td>Antigen</td>		Q/1004	DRB1_1301	VAAMNERI K	57. 4 64.6	2 5495	Antigen
Q712175 DRB1_1301 VAARRSHRE 20.2 1.1808 Antigen DRB1_1301 KVAARRSHR 23.5 1.4005 Antigen Q724J4 DRB1_0101 LHFLWNSNL 527.4 1.2681 Antigen DRB1_1301 IRKKQAGSKK 49.4 2.2596 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 ARRANIRFR 17.4 2.2999 Antigen DRB1_1301 FQARRANIRF 44.7 1.9086 Antigen DRB1_1301 KKLGARLER 60.8 1.1766 Antigen DRB1_0101 FANIRPIQV 76 1.1402 Antigen<		071775	DRB1_1301	I STKGKNRK	8.8	1 9105	Antigen
DRB1_1301 WHARBIAL 20.2 1.1000 Halgar DRB1_1301 KVAARRSHR 23.5 1.4005 Antigen Q724J4 DRB1_0101 LHFLWNSNL 527.4 1.2681 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 MKGQAGSKK 49.4 2.2596 Antigen DRB1_1301 ARRANIRFR 17.4 2.2999 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 KKLGARLER 60.8 1.1766 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen		QIILIS	DRB1_1301	VAARRSHRF	20.2	1.1808	Antigen
Q724J4 DRB1_0101 LHFLWNSNL 527.4 1.2681 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen DRB1_1301 MKGQAGSKK 49.4 2.2596 Antigen Q71W17 DRB1_1301 ARRANIRFR 17.4 2.2999 Antigen DRB1_1301 QARRANIR 49.8 1.458 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 KKLGARLER 60.8 1.1766 Antigen Q71Y34 DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 <td></td> <td></td> <td>DRB1_1301</td> <td>KVAARRSHR</td> <td>23.5</td> <td>1.1005</td> <td>Antigen</td>			DRB1_1301	KVAARRSHR	23.5	1.1005	Antigen
Q71W17 DRB1_1301 IRLKLKSSV 15.1 1.403 Antigen Q71W17 DRB1_1301 MKGQAGSKK 49.4 2.2596 Antigen Q71W17 DRB1_1301 ARRANIRFR 17.4 2.2999 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen Q71Y34 DRB1_0101 FANIRPIQV 76 1.1402 Antigen Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		072414	DRB1_0101	I HEI WNSNI	527 A	1.4005	Antigen
Q71W17 DRB1_1301 MKGQAGSKK 49.4 2.2596 Antigen Q71W17 DRB1_1301 ARRANIRFR 17.4 2.2999 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen Q71Y34 DRB1_0101 FANIRPIQV 76 1.1402 Antigen Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		Q724J4	DRB1_0101	IDI KI KSSV	15.1	1.2031	Antigen
Q71W17 DRB1_1301 ARRANIRFR 17.4 2.2590 Antigen DRB1_1301 ARRANIRFR 17.4 2.2999 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen			DRD1_1301	MKCOACSKK	10.1	2 2506	Antigon
Q71W17 DKB1_1301 AKKANKFK 17.4 2.2999 Antigen DRB1_1301 QARRANIRF 44.7 1.9086 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 KKLGARLER 60.8 1.1766 Antigen DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		071W17	DRB1_1301	A DD A NIDED	49.4	2.2390	Antigen
DKB1_1301 QARKANKF 44.7 1.3080 Antigen DRB1_1301 FQARRANIR 49.8 1.458 Antigen DRB1_1301 KKLGARLER 60.8 1.1766 Antigen Q71Y34 DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		Q/1W1/	DRB1_1301		17.4	1.0096	Antigen
Q71Y34 DRB1_0101 FANIRPIQV 449.5 1.458 Antigen Q71XR2 DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen Q71XR2 DRB1_0101 FANIRPIQV 76 1.1402 Antigen DRB1_1301 LAFKVKHSS 486.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen			DRD1_1301		44.7	1.9080	Antigen
Q71Y34 DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen			DRB1_1301	FUARRANIR	49.8	1.438	Antigen
Q71Y34 DRB1_0101 FANIRPIQV 449.7 1.1402 Antigen DRB1_0701 FANIRPIQV 76 1.1402 Antigen Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		0713/24	DRB1_1301	KKLGAKLEK	60.8	1.1700	Antigen
Q71XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		Q/1134	DRB1_0101	FANIRPIQV	449.7	1.1402	Antigen
Q/1XR2 DRB1_0101 AIFIRAPYL 886.2 1.4467 Antigen DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		0713/00	DRB1_0/01	FANIRPIQV	/6	1.1402	Antigen
DRB1_1301 LAFKVKHSS 48.5 1.2632 Antigen DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen		Q/IXR2	DRB1_0101	AIFIRAPYL	886.2	1.4467	Antigen
DRB1_1301 IFIRAPYLI 62.4 1.6671 Antigen			DRB1_1301	LAFKVKHSS	48.5	1.2632	Antigen
		0	DRB1_1301	IFIRAPYLI	62.4	1.6671	Antigen
Q71ZE0 DRB1_0101 FDCVLPTRI 357 1.5369 Antigen		Q71ZE0	DRB1_0101	FDCVLPTRI	357	1.5369	Antigen
Q71ZE0 DRB1_0101 FDCVLPTRI 357 1.5369 Antigen		Q71ZE0	DRB1_0101	FDCVLPTRI	357	1.5369	Antigen
DRB1_0701 FDCVLPTRI 25.3 1.5369 Antigen			DRB1_0701	FDCVLPTRI	25.3	1.5369	Antigen
DRB1_0701 CEETFGIRL 66 2.4185 Antigen			DRB1_0701	CEETFGIRL	66	2.4185	Antigen
Q71XX6 DRB1_0701 FKATGGKRI 25.8 1.4894 Antigen		Q71XX6	DRB1_0701	FKATGGKRI	25.8	1.4894	Antigen
DRB1_1301 VILQVFYFK 63.3 1.8276 Antigen			DRB1_1301	VILQVFYFK	63.3	1.8276	Antigen
DRB1_1301 LLLIGIIFV 63.9 1.1184 Antigen			DRB1_1301	LLLIGIIFV	63.9	1.1184	Antigen
Q71Y46 DRB1_0101 FNVLDSRVL 469 1.38 Antigen		Q71Y46	DRB1_0101	FNVLDSRVL	469	1.38	Antigen
DRB1_0701 FNVLDSRVL 70.1 1.38 Antigen			DRB1_0701	FNVLDSRVL	70.1	1.38	Antigen
Q71WP0 DRB1_0101 FIVVDPMLA 640 1.8053 Antigen		Q71WP0	DRB1_0101	FIVVDPMLA	640	1.8053	Antigen
Q720A5 DRB1_0701 IKEFKPKMV 117 1.1015 Antigen		Q720A5	DRB1_0701	IKEFKPKMV	117	1.1015	Antigen
Q71WP7 DRB1_1301 LRLDLAAYR 58.4 1.7082 Antigen		Q71WP7	DRB1_1301	LRLDLAAYR	58.4	1.7082	Antigen
Q720D7 DRB1_0101 VILAYAPLL 1236.9 1.2361 Antigen		Q720D7	DRB1_0101	VILAYAPLL	1236.9	1.2361	Antigen
DRB1_0701 LGATNSFRV 97.1 1.2028 Antigen			DRB1_0701	LGATNSFRV	97.1	1.2028	Antigen
Q720T3 DRB1_0101 ALLMPLPVA 654.6 1.5696 Antigen		Q720T3	DRB1_0101	ALLMPLPVA	654.6	1.5696	Antigen
DRB1_0101 FLGVPWWPV 721.2 2.0565 Antigen			DRB1_0101	FLGVPWWPV	721.2	2.0565	Antigen
DRB1_0101 LMPLPVAII 929.1 1.4677 Antigen			DRB1_0101	LMPLPVAII	929.1	1.4677	Antigen
DRB1_0101 FYFLFYGSL 1330 1.6406 Antigen			DRB1_0101	FYFLFYGSL	1330	1.6406	Antigen
DRB1_0101 VALLMPLPV 1365.6 1.8132 Antigen			DRB1_0101	VALLMPLPV	1365.6	1.8132	Antigen
DRB1_0701 FLGVPWWPV 29.7 2.0565 Antigen			DRB1_0701	FLGVPWWPV	29.7	2.0565	Antigen
DRB1_0701 IIGAWNWLI 309.5 1.666 Antigen			DRB1_0701	IIGAWNWLI	309.5	1.666	Antigen
Q71YI4 DRB1_0701 SGETLSVKV 325.2 2.4375 Antigen		Q71YI4	DRB1_0701	SGETLSVKV	325.2	2.4375	Antigen
DRB1_1301 LRVTPGIRL 32.6 2.4375 Antigen			DRB1_1301	LRVTPGIRL	32.6	2.4375	Antigen
DRB1 1301 FLRVTPGIR 65.4 1.2425 Antigen			DRB1 1301	FLRVTPGIR	65.4	1.2425	Antigen
Q71WT9 DRB1_0701 VSLRVGMEI 216.6 1.6096 Antigen		Q71WT9	DRB1 0701	VSLRVGMEI	216.6	1.6096	Antigen
DRB1 1301 IGETERRRK 37.9 1.3502 Antigen			DRB1 1301	IGETERRRK	37.9	1.3502	Antigen
O720J1 DRB1 0701 IEVTPDYLM 299.3 1.7114 Antigen		O720J1	DRB1 0701	IEVTPDYLM	299.3	1.7114	Antigen
071ZZ0 DRB1 1301 THLKTRPKK 20.2 1.3476 Antigen		071ZZ0	DRB1 1301	THLKTRPKK	20.2	1.3476	Antigen
DRR1 1301 I RTHI KTRP 22.8 1 2703 Antigen		X, 1220	DRB1_1301	LRTHLKTRP	22.2	1.2793	Antigen
$O71XV7 \qquad DRB1 0101 \qquad FLYVVVYSI \qquad 1303.6 \qquad 1.213 \qquad Antigen$		071XV7	DRB1_0101	FLYVVVYSI	1393.6	1.213	Antigen
DRB1 0701 FAVEPSESI 53.6 1.810 Anticon		X, 111 Y /	DRB1_0701	FAVEPSESI	53.6	1.215	Antigen
DRB1_0701 IKWAKWMEV 123.5 1.348 Antigen			DRB1_0701	IKWAKWMFV	123.5	1.348	Antigen

Protein ID Allele Binding affin-VaxiJen score Antigen/ Peptide ity [nM] nonantigen Q724E9 DRB1_0101 FSAGMGAEA 959.2 1.5015 Antigen DRB1_0701 LVEGRAIRL 269.1 1.5701 Antigen DRB1_1301 TKSKVRRER 13.3 1.2742 Antigen DRB1_1301 GQRRTRAIR 33.3 1.2488 Antigen DRB1_1301 LKGKQGRFR 51 1.7176 Antigen DRB1_1301 55.5 1.6836 LKSAQGQRR Antigen DRB1_1301 EVTKSKVRR 59.3 1.1113 Antigen DRB1_1301 LIFNTILPK 65.3 1.134 Antigen Q71WI0 DRB1_0101 FALHYPYEL 1003.9 1.4132 Antigen DRB1_0701 FALHYPYEL 319.5 1.4132 Antigen 071Z37 DRB1_0101 FLFAPHVHP 425 1.8183 Antigen 125 DRB1_0101 IAFLFAPHV 1.9413 Antigen DRB1_0101 LYTLRPEDV 1060.8 1.3501 Antigen Q71XV6 DRB1_0701 FSMVLSLVF 100 1.4972 Antigen DRB1_0701 ASRSKSNRL 302 1.1981 Antigen DRB1_0701 YIMALHFGI 307 1.9206 Antigen 308 DRB1_0701 YALTIYTYL 1.1261 Antigen DRB1_1301 **IVLLALMIF** 28 1.9817 Antigen Q724M3 DRB1_0101 FDVKMGVRI 1025.4 1.9181 Antigen DRB1_0701 FDVKMGVRI 320 1.9181 Antigen DRB1_1301 VKMGVRITI 36 1.2822 Antigen Q71WH2 DRB1_1301 VRLNATRGR 13 1.8274 Antigen DRB1_1301 IKKLALKIY 69 1.2527 Antigen Q71VQ8 DRB1_0701 **IVFPLSWTI** 300 1.6433 Antigen DRB1 1301 LLIMPLMIK 24 2.2056 Antigen Q71ZU1 DRB1_0101 1353.2 LIQMPILMA 1.3037 Antigen Q720A3 712 1.5796 DRB1_0101 LHLIPVNMK Antigen DRB1_0101 LIGLPIRIT 1193 1.6981 Antigen DRB1_1301 IYKYDVRFK 53 1.8026 Antigen Q720A7 DRB1_1301 VRVNVMGYR 20 1.4928 Antigen DRB1_1301 LRLSNFMLW 55 1.2577 Antigen Q720J2 DRB1_0101 WLNMPDMTV 1064.6 1.3955 Antigen Q71XU1 DRB1_0701 ILNFTPARI 108 1.1713 Antigen DRB1_0701 LNFTPARIS 248.4 1.4755 Antigen DRB1_1301 ILNFTPARI 54.6 1.1713 Antigen Q71WU5 DRB1_0101 PISIISARI 1514.9 1.1708 Antigen DRB1_0701 PISIISARI 121.3 1.1708 Antigen Q71YA9 DRB1_0701 ATGTTGLRI 122.2 2.2883 Antigen Q724F0 DRB1_0101 FRTLRPTDG 368.9 1.165 Antigen DRB1_0101 LINIRPVVA 1366 1.2121 Antigen DRB1_0701 78.9 1.4245 VEHVEAREI Antigen DRB1_1301 22.2 1.3688 Antigen LRVKLRLIN

Table 2 (continued)

Protein ID	Allele	Peptide	Binding affin- ity [nM]	VaxiJen score	Antigen/ non- antigen
Q71WP3	DRB1_0101	NTLTLGLRL	518	1.6477	Antigen
	DRB1_0101	MKFLFPLKL	612.8	2.3447	Antigen
	DRB1_0101	MLGLPFQIA	1397.6	1.8635	Antigen
	DRB1_0701	NTLTLGLRL	80.1	1.6477	Antigen
	DRB1_0701	MKFLFPLKL	175.8	2.3447	Antigen
	DRB1_0701	VTLTLAIMV	181.1	1.2651	Antigen
	DRB1_1301	ICTRNLQRR	16.9	1.1843	Antigen
Q722W7	DRB1_0101	WVMHLDAMV	1508.3	1.4715	Antigen
	DRB1 0701	IVYEVSWRY	223.4	1.2052	Antigen
	DRB1_0701	YHFYFAHAL	234.2	1.4315	Antigen
	DRB1_1301	LMGRSGRRG	11.8	1.4813	Antigen
	DRB1_1301	LRITMLLMR	26.9	1.1065	Antigen
	DRB1_1301	OLMGRSGRR	27.3	1 1831	Antigen
	DRB1_1301	KI STKI KRK	36.7	1 3477	Antigen
O71YH0	DRB1_0101	CTI I YAFPI	185.7	2 1684	Antigen
Q/11110	DRB1_0101	SYWLIGI PV	452.6	1 3982	Antigen
	DRB1_0701	CIGIPAFEI	229.8	1.5702	Antigen
	DRB1_0701		260.9	1.0785	Antigen
	DRB1_0701	ΟΤΙ Ι ΥΔΕΡΙ	311.2	2 1684	Antigen
	DPP1 1201		8.4	1 1456	Antigon
	DRB1_1301	IDVDKTEOK	0.4 17.8	1.1450	Antigen
	DRB1_1301	A FIL SIDVD	30.5	1.0151	Antigen
	DRB1_1301	I SIDVDKTE	59.5 45 7	1.4081	Antigen
	DRB1_1301	I TI ESMTEE	45.7	1.7095	Antigon
071WP6	DRD1_1301	VIDCICHNI	410.0	1.2134	Antigen
Q/IWB0	DRB1_0101	VPI SNCIEV	419.9	1.1552	Antigen
071VP0	DRB1_0/01	V KLSINGIE V	41.0	1.555	Antigen
Q/11b9	DRB1_0101	FLKIDFFIL	199.4	2.5167	Antigen
	DRB1_0101		324.2	2.14/0	Antigen
0713004	DRB1_0/01	FLKIDPPIL	101.7	2.3187	Antigen
Q/1VR4	DRB1_0101	KLNLHAI I V	1297.1	1.0173	Antigen
0711100	DRB1_1301	LOFUDALAL	55.6	1.2977	Antigen
Q/1W89	DRB1_0101	LSFLPALAL	91.8	1.5837	Antigen
	DRB1_0101	YILLPLSLI	150	1.4583	Antigen
	DRB1_0101	FSLAFNIAA	398.7	1.4513	Antigen
	DRB1_0101		879.3	1.4451	Antigen
	DRB1_0101	FLPALALGP	996.5	1.3317	Antigen
	DRB1_0101	LILVPPLLT	1544.3	2.0559	Antigen
	DRB1_0701	LSFLPALAL	97.5	1.5837	Antigen
	DRB1_0701	LSFSLAFNT	155.2	1.688	Antigen
07111/01	DRB1_0701	LLLVLAVPL	211.1	1.53	Antigen
Q71W91	DRB1_0101	VNVLQVNLA	587.2	1.403	Antigen
Q71WP8	DRB1_0101	LEVLLPQYV	1295.8	1.246	Antigen
Q71WG3	DRB1_1301	VKGGRRFRF	39.8	1.694	Antigen
Q71Z71	DRB1_1301	ISVREKSAK	56	1.548	Antigen
Q722Y1	DRB1_0101	GVMLPLKLS	254.4	1.104	Antigen
	DRB1_0101	FQIELGHAA	324.6	1.288	Antigen

Protein ID Allele Binding affin-VaxiJen score Antigen/ Peptide ity [nM] nonantigen Q71WF2 **KVHPIGMRI** DRB1_0701 181.4 1.3023 Antigen DRB1_1301 IKTQVSGRL 19.6 1.16 Antigen DRB1_1301 MRAGAKGIK 50.5 1.27 Antigen DRB1_1301 LRIRDYVAK 51.4 1.181 Antigen O722Y9 DRB1_1301 34.9 IKLRKTQPR 1.462 Antigen Q71WF1 DRB1_1301 VRIAPRKAR 27 1.1447 Antigen DRB1_1301 GRASAINKR 44 1.264 Antigen Q71ZP6 DRB1_0101 YKLLNPTLG 86.8 1.307 Antigen DRB1_0101 FLNIRLKPV 485.3 1.9058 Antigen DRB1_0101 ILSMQLSFA 540.1 1.2557 Antigen DRB1_0101 599.5 LNLLFGIPL 1.7237 Antigen DRB1_0101 LAIVPAVII 777.5 1.356 Antigen DRB1 0101 LSMOLSFAV 1348.6 1.566 Antigen DRB1_0701 **FSLTIALLI** 22.4 1.852 Antigen DRB1_0701 IDSTFSLTI 57.8 1.4124 Antigen DRB1_0701 FLNIRLKPV 62.9 1.906 Antigen DRB1_0701 ISWAVAIFI 72.9 1.347 Antigen 111.4 1.277 DRB1_0701 IGSAIALNL Antigen DRB1_0701 LAIVPAVII 184 1.356 Antigen 30.9 DRB1_1301 LNIRLKPVV 2.189 Antigen Q71WE9 DRB1_0701 IKVGNALEL 51 1.204 Antigen DRB1_1301 60.7 1.322 Antigen LKKKAGRNN DRB1_1301 VRHHGGGHK 63.8 2.522 Antigen **O71WB7** DRB1_1301 LEVKARRVG 53 1.551 Antigen DRB1_1301 **IEVRADRRS** 60.7 1.989 Antigen DRB1_1301 65.1 MMVDGKRGK 1.375 Antigen O71WH0 DRB1_1301 SYRGMRHRR 9 1.4454 Antigen DRB1_1301 TKNNARTRK 38.1 2.1367 Antigen Q71XE5 DRB1_0701 FVSGLSFHV 35.1 1.487 Antigen DRB1_1301 KQLKIRQIR 53.8 1.389 Antigen Q71XX1 DRB1_0101 NIDIKGRLI 1319.9 1.353 Antigen Q71YK6 DRB1_0701 IFDVRSEHV 179.8 1.5294 Antigen Q71WE5 DRB1_1301 MAKQKIRIR 18.8 1.2116 Antigen DRB1_1301 FEMRTHKRL 27.8 1.1916 Antigen DRB1_1301 IRLKAYDHR 28.8 1.7067 Antigen DRB1_1301 AKQKIRIRL 37.3 1.7363 Antigen DRB1_1301 **QKIRIRLKA** 46.2 1.7022 Antigen DRB1_1301 55.2 IRIRLKAYD 1.8524 Antigen DRB1_1301 QFEMRTHKR 68.6 1.7135 Antigen Q71WF6 DRB1_1301 VRTKSGARR 5.6 1.944 Antigen Q71WH1 DRB1_1301 MARKTNTRK 5.2 1.6203 Antigen DRB1_1301 RKTNTRKRR 5.5 2.5417 Antigen DRB1_1301 ARKTNTRKR 10.3 2.2271 Antigen DRB1_1301 TNTRKRRVK 26.3 2.1039 Antigen DRB1_1301 TRKRRVKKN 55.9 1.5039 Antigen 1.8576 DRB1_1301 NTRKRRVKK 62 Antigen

 Table 2 (continued)

 Table 2 (continued)

Protein ID	Allele	Peptide	Binding affin- ity [nM]	VaxiJen score	Antigen/ non- antigen
Q725B8	DRB1_1301	GRRGGRRRK	7.1	3.0668	Antigen
	DRB1_1301	RRGGRRRKK	17.1	2.833	Antigen
	DRB1_1301	GGRRGGRRR	25.2	3.1722	Antigen
Q71WV5	DRB1_1301	VKKRSAKRA	14.9	1.3995	Antigen
	DRB1_1301	LNARTLERK	16.7	1.6232	Antigen
	DRB1_1301	VRLKSGTRG	19.6	1.5481	Antigen
	DRB1_1301	VSKSGINHR	44.8	1.3402	Antigen
	DRB1_1301	LNARTLERK	16.7	1.6232	Antigen
	DRB1_1301	VRLKSGTRG	19.6	1.5481	Antigen
	DRB1_1301	VSKSGINHR	44.8	1.3402	Antigen
Q71WG2	DRB1_1301	KVRKKRHAR	7.7	1.6463	Antigen
	DRB1_1301	VRKKRHARV	12.6	1.3471	Antigen
	DRB1_1301	RHARVRSKI	27.1	1.4108	Antigen
	DRB1_1301	KKRHARVRS	38.4	2.0868	Antigen
	DRB1_1301	RKKRHARVR	47.2	2.0804	Antigen
	DRB1_1301	NKVRKKRHA	59.3	1.1365	Antigen
Q71WE8	DRB1_1301	AGYTNKRRK	46.9	1.237	Antigen
Q71YD4	DRB1_1301	FGISRIRFR	48.6	1.1227	Antigen
Q71YN5	DRB1_1301	TVTRKRRKK	2.7	1.1019	Antigen
	DRB1_1301	GTVTRKRRK	15.8	1.2113	Antigen
	DRB1_1301	GGTVTRKRR	31	1.6998	Antigen
Q721R7	DRB1_1301	ARLRTTGGR	14	1.7495	Antigen
	DRB1_1301	RLRTTGGRY	64.9	1.4507	Antigen
Q71ZZ5	DRB1_1301	MNVRANRVS	41.7	2.0256	Antigen
	DRB1_1301	GRRIRLRKV	60.1	1.6184	Antigen
Q720A8	DRB1_0101	LRLSIPQLT	375.6	1.2897	Antigen
	DRB1_0701	LRLSIPQLT	192.5	1.2897	Antigen
Q721Y1	DRB1_0701	LRITLNLAL	19.5	1.9824	Antigen
	DRB1_1301	ILLRITLNL	32.3	1.4731	Antigen
	DRB1_1301	LLLVAALFL	51.9	1.2854	Antigen
Q71YM9	DRB1_0101	LRNLRGKAA	476.7	1.2468	Antigen
	DRB1_0701	TVRVHAKVV	152.6	1.3034	Antigen
	DRB1_1301	VRVHAKVVE	67.1	1.564	Antigen
	DRB1_1301	RRGKVRRAK	20.2	1.3055	Antigen
	DRB1_1301	LRGKAARIK	17.4	2.0521	Antigen
Q71WG4	DRB1_1301	AKLEITLKR	51.3	1.1423	Antigen
Q71YN4	DRB1_0701	FKRTGSGKL	34.3	1.1993	Antigen
	DRB1_1301	THRGSAKRF	43.7	1.0624	Antigen
	DRB1_1301	QKQKRKLRK	46.1	1.1816	Antigen
Q71WH3	DRB1_1301	LGRTSSQRK	33.5	1.2846	Antigen
Q71ZY7	DRB1_1301	LKKYCPRLR	50.8	2.0807	Antigen
	DRB1_1301	KKYCPRLRR	61.5	1.5286	Antigen

Protein ID	Allele	Peptide	Binding affin- ity [nM]	VaxiJen score	Antigen/ non- antigen
Q71XW7	DRB1_1301	SKAKKRKRR	5.8	1.8899	Antigen
	DRB1_1301	KKRKRRTHV	11.7	1.4013	Antigen
	DRB1_1301	AKKRKRRTH	15.7	1.6556	Antigen
	DRB1_1301	RTSKAKKRK	18.1	1.9221	Antigen
	DRB1_1301	KRKRRTHVK	21.3	1.6065	Antigen
	DRB1_1301	TSKAKKRKR	23.1	1.7453	Antigen
	DRB1_1301	KAKKRKRRT	24.4	1.7483	Antigen
	DRB1_1301	RRTSKAKKR	26	1.7169	Antigen
	DRB1_1301	RKRRTHVKL	39.5	1.4259	Antigen
Q723G3	DRB1_1301	ARRTSKAKK	15.4	1.4443	Antigen
	DRB1_1301	SKAKKNKRR	29.1	1.707	Antigen
	DRB1_1301	KAKKNKRRT	46.4	1.7778	Antigen
Q71WV3	DRB1_0101	FKYGIPIDA	297	1.6186	Antigen
	DRB1_1301	ISHRDMKRR	11.9	1.5539	Antigen
	DRB1_1301	LMFTLPFYK	44.9	1.9589	Antigen
	DRB1_1301	ALVMDLRGR	45.8	1.1548	Antigen
	DRB1_1301	MAPRELRER	51.1	1.1283	Antigen
	DRB1_1301	SHRDMKRRK	64	1.6218	Antigen
	DRB1_1301	LLMFTLPFY	68.2	2.632	Antigen
	DRB1_1301	SRYKETRRH	69.9	1.0813	Antigen
Q71ZJ5	DRB1_0101	FRFVPINNF	1098	1.5957	Antigen
	DRB1_0701	FRFVPINNF	83.9	1.5957	Antigen
	DRB1_0701	IQPVGSKNL	287.2	0.534	Antigen
Q721N6	DRB1_1301	QMVQNRHGK	18	1.5447	Antigen
Q71ZK1	DRB1_1301	KKSEAARKR	46.5	1.9356	Antigen
Q71ZD0	DRB1_1301	MLKFDIQHF	45	1.2032	Antigen
Q71WF4	DRB1_0101	LFNLRFQLA	1029	2.5288	Antigen
Q71YL9	DRB1_1301	MAVKIRLKR	4.3	1.4155	Antigen
	DRB1_1301	AVKIRLKRI	55.1	1.4342	Antigen
Q71YK0	DRB1_1301	RKSRSGNKR	40.5	2.7338	Antigen
Q71WI2	DRB1_1301	LLTRDPRMK	16.6	1.3863	Antigen
	DRB1_1301	KSSVARVRL	68.6	1.0414	Antigen
Q71VQ6	DRB1_1301	ASRRRKGRK	8.3	2.0002	Antigen
	DRB1_1301	SRRRKGRKV	12.1	1.7764	Antigen
	DRB1_1301	MSTKNGRRV	13.5	1.7661	Antigen
	DRB1_1301	FRTRMSTKN	39.7	1.2896	Antigen
	DRB1_1301	RMSTKNGRR	49.3	2.0073	Antigen
Q722D6	DRB1_0101	YALLFFPYA	1222	1.9423	Antigen
	DRB1_0701	IFLFAANIL	179.2	1.1164	Antigen
	DRB1_1301	LSVKLRSRG	15	1.128	Antigen
	DRB1_1301	VLSVKLRSR	21.1	1.3894	Antigen

793

Table 2 (continued)	Protein ID	Allele	Peptide	Binding affin- ity [nM]	VaxiJen score	Antigen/ non- antigen
	Q71XL9	DRB1_0101	GIILLGFRL	330.6	1.0131	Antigen
		DRB1_0101	YFLAKLPFL	673.5	1.4522	Antigen
		DRB1_0101	FLIAALCLS	844.4	1.2298	Antigen
		DRB1_0101	FLIAMSMGG	884.2	1.1022	Antigen
		DRB1_0101	FLAKLPFLM	891	1.7779	Antigen
		DRB1_0101	FLVICAYFL	1342	2.0765	Antigen
		DRB1_0101	YFLIAMSMG	1357	1.1587	Antigen
		DRB1_0101	YGIALTFCI	1600	1.7051	Antigen
		DRB1_0701	VIYTLIYPI	20.1	1.3475	Antigen
		DRB1_0701	FLVICAYFL	125.7	2.0765	Antigen
	Q71XA1	DRB1_0701	ITISLGFYL	56.9	1.6467	Antigen
	A6X137	DRB1_1301	AHAKIRERL	32.2	1.2949	Antigen
	Q71Z99	DRB1_0701	PQVTVSLVF	92.9	1.1655	Antigen
		DRB1_1301	VILLKLFHV	49.4	1.5441	Antigen
	Q724P3	DRB1_1301	IRCKYTKTR	22.7	2.0203	Antigen
		DRB1_1301	RCKYTKTRR	43	1.5601	Antigen
	Q71ZL4	DRB1_1301	LMLDIRYRH	33.2	1.656	Antigen
		DRB1_1301	SLMLDIRYR	35.4	1.4323	Antigen
	Q2N761	DRB1_0101	LLSLSPELF	1010	1.2376	Antigen
		DRB1_0101	WLLSLSPEL	1136	2.0048	Antigen
		DRB1_0101	NVAIRTLRL	1262	1.4269	Antigen
		DRB1_0701	WLLSLSPEL	59.8	2.0048	Antigen
		DRB1_0701	MVTTVHARL	241.6	1.3229	Antigen
		DRB1_0701	NVAIRTLRL	244.4	1.4269	Antigen
		DRB1_1301	ARVRLTSGR	28.7	1.3033	Antigen
		DRB1_1301	MVTTVHARL	31.9	1.3229	Antigen
		DRB1_1301	VAIRTLRLT	34.2	1.1019	Antigen
	L9WZX9	DRB1_1301	AHRKAARER	17.4	1.422	Antigen
		DRB1_1301	ALLWLFPRF	59.1	2.2918	Antigen
	A0A0X1KHF9	DRB1_0101	CSNIEGVHV	1163	1.8716	Antigen
		DRB1_0701	ITQSLSAKV	20.1	1.1418	Antigen
		DRB1_0701	LSIDASFGL	320.4	1.1112	Antigen
	Q1KT48	DRB1_0701	LKLACAKAF	89.5	1.2066	Antigen

Cut off value for the VaxiJen server is 1.1

The top 20 selected epitopes are represented in bold

by Swiss Model. Proteins with PDB ID 4AH2, 3C5J, and 6CQL were used as templates for alleles HLA DRB1_0101, HLA DRB1_0701, and HLA DRB1_1301. Visualization of the tertiary structures was done by the PyMOL visualization tool. Molecular docking between epitope and its corresponding allele was performed by AutoDock Vina software. Based on low binding energy, 4 peptides were selected viz., CEETFGIRL, MKFLFPLKL, FLKIDPPIL, and VRH-HGGGHK. CEETFGIRL showed the energy of – 6.7 kcal/mol and 6 hydrogen bonds. MKFLFPLKL showed the

energy of - 6.9 kcal/mol and 2 hydrogen bonds. FLKIDP-PIL showed the energy of - 7.3 kcal/mol and 6 hydrogen bonds. VRHHGGGHK showed the energy of - 6.7 kcal/ mol and 6 hydrogen bonds. These 4 epitopes were selected on low binding energy as low energy means high stability. Most promiscuous B cell epitope which is a nano peptide, must not be toxic and therefore toxicity analysis must be performed. Toxin Pred server is used for this analysis. This server also anticipates various physicochemical properties of the epitopes like molecular weight, hydrophobicity, and Fig. 1 Modeled structure of HLA class II alleles—a molecular structure of HLA DRB1_0101, b molecular structure of HLA DRB1_0701, c molecular structure of HLA DRB1_1301



 Table 3
 List showing Binding energy of 20 selected epitopes while interacting with its corresponding allele, as anticipated by AutoDock Vina software

S. no.	Peptide	Allele	Energy (kcal/ mol)
1	VAAMNFRLK	DRB1_1301	- 5.8
2	MKGQAGSKK	DRB1_1301	- 5.1
3	ARRANIRFR	DRB1_1301	- 5.7
4	CEETFGIRL	DRB1_0701	- 6.7
5	SGETLSVKV	DRB1_0701	- 6.5
6	LRVTPGIRL	DRB1_1301	- 6.3
7	ATGTTGLRI	DRB1_0701	- 6.3
8	MKFLFPLKL	DRB1_0101	- 6.9
9	MKFLFPLKL	DRB1_0701	- 6.5
10	FLKIDPPIL	DRB1_0101	- 7.3
11	FLKIDPPIL	DRB1_0701	- 6.5
12	VRHHGGGHK	DRB1_1301	- 6.7
13	RKTNTRKRR	DRB1_1301	- 5.2
14	ARKTNTRKR	DRB1_1301	- 5.7
15	RRGGRRRKK	DRB1_1301	- 5.2
16	GGRRGGRRR	DRB1_1301	- 5.9
17	LLMFTLPFY	DRB1_1301	- 6.4
18	LFNLRFQLA	DRB1_0101	- 6.5
19	RKSRSGNKR	DRB1_1301	- 5.5
20	ALLWLFPRF	DRB1_1301	- 6.3

Selected epitopes are represented in bold

hydrophilicity. MHC Pred server was used to anticipate the binding intensity of epitopes with allele's viz., HLA DRB1_0101, HLA DRB1_0401, and HLA DRB1_0701.



Fig. 2 This Docked result depicts the interaction analysis of epitope CEETFGIRL (represented with cyan color) with 3C5J receptor (represented with forest green color). Showing the epitope interacting with 3C5J receptor with the help of 6 hydrogen bonds (Color figure online)

Epitopes viz., CEETFGIRL and VRHHGGGHK were found to bind with HLA DRB1_0101 and HLA DRB1_0401, respectively. Both FLKIDPPIL and MKFLFPLKL were found to bind with HLA DRB1_0101 and HLA DRB1_0701. Binding energy prediction is given in the form of IC₅₀ value. Epitopes having an IC₅₀ value greater than 500 nM are not considered in this analysis. Population coverage analysis is one of the most important investigations need to be done in computational biology. Population coverage analysis of all 4 epitopes was analyzed by the IEDB population coverage tool. Based on both low binding energy and high population



Fig. 3 This Docked result depicts the interaction analysis of epitope MKFLFPLKL (represented with cyan color) with 4AH2 receptor (represented with forest green color). Showing the epitope interacting with 4AH2 receptor with the help of which 2 hydrogen bonds (Color figure online)



Fig. 4 This Docked result depicts the interaction analysis of epitope FLKIDPPIL (represented with cyan color) with 4AH2 receptor (represented with forest green color). Showing the epitope interacting with 4AH2 receptor with the help of 6 hydrogen bonds (Color figure online)

coverage, worldwide epitope FLKIDPPIL was selected. To check the binding energy of epitope FLKIDPPIL with its corresponding 4AH2 receptor molecular dynamics simulation study was performed by using MD Web. RMSD and B factor plot was used to interpret the result of the simulation. After all these vigorous steps of the investigation, epitope FLKIDPPIL proved to be the most eligible candidate that should be used for vaccine designing. Reverse vaccinology has been proved as one of the most powerful weapons to combat some deadly bacterial diseases and had shown tremendous results also. First and foremost, a peptide-based



Fig. 5 This Docked result depicts the interaction analysis of epitope VRHHGGGHK (represented with cyan color) with 6CQL receptor (represented with forest green color). Showing the epitope interacting with 6cql receptor with the help of 6 hydrogen bonds (Color figure online)

vaccine using the reverse vaccinology approach was created against *E. coli* in the year 1985 (Jacob et al. 1985). It has been proved effective against tuberculosis (Mustafa 2013) and many more pathogenic diseases. The identification of antigenic peptides by using a reverse vaccinology approach has been found effective against *Staphylococcus aureus* (Oyama et al. 2019). From this research work, we found during the identification and characterization of epitopes for the utility of vaccine designing against *Listeria monocytogenes*, the epitope FLKIDPPIL was non-allergic, non-toxic, highly antigenic, and can provoke a better immune response.

Conclusion

Despite major advancements in the field of technology, society and mankind have been plagued by several kinds of lifethreatening diseases. Although vigorous research is going on, on several deadly diseases in various parts of the world. But still, some foodborne diseases are under-reported and Listeriosis is one of them. In such conditions, computational vaccine technology is one of the best alternatives to deal with such diseases. Computational vaccine technology is a boon in research domains as it accelerates the process of epitope screening and vaccine designing and development. It is a branch of vaccinology that is based on the central idea of solving vaccine development by using a computerdriven algorithm. Listeriosis is still under-reported in many countries of the world. Computational vaccine technology is going to create some awareness and will bring out the best treatment and remedy for the disease. In this research work, after performing molecular docking, 4 epitopes were

Table 4 Result of toxicity analysis of selected epitopes as	Epitope	SVM score	Toxic/nontoxic	Molecular weight	Hydrophobicity	Hydrophilicity
analyzed by Toxin Pred along	CEETFGIRL	- 0.73	Non toxic	1067.35	- 0.12	0.17
with their physicochemical properties	MKFLFPLKL	- 0.73	Non toxic	1136.64	0.09	- 0.63
	FLKIDPPIL	- 0.85	Non toxic	1055.46	0.13	- 0.41
	VRHHGGGHK	- 1.03	Non toxic	984.23	- 0.34	0.33

 Table 5
 List showing number of HLA binders and binding affinity of anticipated B cell epitopes as investigated by MHCPred tool

EPITOPE	Number of HLA bind- ers	HLA with predicted IC50 (nM) value
FLKIDPPIL	2	HLA-DRB1_0101 (19.19) HLA-DRB1_0701 (195.88)
CEETFGIRL	1	HLA-DRB1_0101 (66.53),
MKFLFPLKL	2	HLA-DRB1_0101 (78.52) HLA-DRB1_0701 (246.04)
VRHHGGGHK	1	HLA-DRB1_0401 (318.42)

IC₅₀ < 500 nM scores are selected (are considered good binders)

screened out. These 4 epitopes viz., CEETFGIRL, MKFLF-PLKL, FLKIDPPIL, and VRHHGGGHK were screened as the most promiscuous B cell epitopes among 299 antigenic sites identified. Low binding energy and population coverage analysis predicted FLKIDPPIL as the most potent epitope. Epitope FLKIDPPIL can elicit a strong immune response in the host against listeriosis. Further wet lab trials can assure the stability as well as the response of the epitope in vitro and in vivo. Reverse vaccinology can be proved as the most powerful approach to find remedies against diseases like listeriosis.



Fig. 6 Graphical representation of Population coverage for epitope MKFLFPLKL and FLKIDPPIL

Fig. 7 Graphical representation of population coverage for epitope CEETFGIRL





Fig. 9 Graphical representation of RMSD for epitope FLKIDPPIL with 4AH2 receptor obtained during simulation studies



Fig. 10 Graphical representation of the B factor plot for epitope FLKIDPPIL with 4AH2 receptor obtained during simulation studies

Compliance with Ethical Standards

Conflict of interest The authors hereby declare they that have no conflict of interest.

Ethical approval The authors did not perform any experiments on human or animals.

References

- Abdelhamed H, Lawrence ML, Ramachandran R, Karsi A (2019) Validation of predicted virulence factors in *Listeria* monocytogenes identified using comparative genomics. Toxins 11:508
- Briers Y, Klumpp J, Schuppler M, Loessner MJ (2011) Genome sequence of *Listeria* monocytogenes Scott A, a clinical isolate from a food-borne listeriosis outbreak. J Bacteriol 193(16):4284–4285
- Brusic V, Petrovsky N (2005) Immunoinformatics and its relevance to understanding human immune disease. Expert Rev Clin Immunol 1(1):145–157
- Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A (2006) Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinform 7(1):153

- Charlier C, Perrodeav E, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury M, Moura A, Goffinet F, Dieye H, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, De Valk H, Lortholary O, Ravaud P, Lecuit M (2017) Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infect Dis 17(5):510–519
- Davies MN, Flower DR (2007) Harnessing bioinformatics to discover new vaccines. Drug Discov Today 12:389–395
- Department of Health. New York State Department of Health (2017) https://www.health.ny.gov/diseases/communicable/listeriosis/ fact_sheet.htm
- Doytchinova IA, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform 8(1):4
- Guan P, Doytchinova IA, Zygouri C, Flower DR (2003) MHCPred, a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res 31:3621–3624
- Gupta S, Kapoor P, Chaudhary K et al (2013) In silico approach for predicting toxicity of peptides and proteins. PLoS ONE 8:e73957
- Hamon M, Bierne H, Cossart P (2006) *Listeria monocytogenes*: a multifaceted model. Nat Rev Microbiol 4(6):423–434
- Hasebe R, Nakao R, Ohnuma A, Yamasaki T, Sawa H, Takai S, Horiuchi M (2017) *Listeria* monocytogenes serotype 4b strains replicate in monocytes/macrophages more than other serotypes. J Vet Med Sci 79(6):962–969
- Hospital A, Andrio P, Fenollosa C, Cicin-Sain D, Orozco M, Gelpí JL (2012) MDWeb and MDMoby: an integrated web-based platform for molecular dynamics simulations. Bioinformatics 28:1278–1279

- Jacob CO, Leitner M, Zamir A, Salomon D, Arnon R (1985) Priming immunization against cholera toxin and *E. coli* heat-labile toxin by a cholera toxin short peptide-beta-galactosidase hybrid synthesized in *E. coli*. EMBO J 4(12):3339–3343
- Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M (2018) Improved methods for predicting peptide binding energy to MHC class II molecules. Immunology 154:394–406
- Kaushik V (2019) In Silico identification of epitope-based peptide vaccine for Nipah virus. Int J Pept Res Ther 26:1147–1153
- Khan F, Srivastava V, Kumar A (2019) Computational identification and characterization of potential T-cell epitopes for the utility of vaccine design against Enterotoxigenic *Escherichia coli*. Int J Pept Res Ther 25:289–302
- Lee DT, Park CJ, Peterec S, Morotti R, Cowles RA (2019) Outcomes of neonates with listeriosis supported with extracorporeal membrane oxygenation from 1991 to 2017. J Perinatol 40(1):105–111
- Listeria (listeriosis) | Listeria | cdc (2019) https://www.cdc.gov/liste ria/index.html
- Mustafa AS (2013) In silico analysis and experimental validation of *Mycobacterium tuberculosis*-specific proteins and peptides of *Mycobacterium tuberculosis* for immunological diagnosis and vaccine development. Med Princ Pract 22(suppl 1):43–51
- Oyama LB, Olleik H, Teixeira CAN, Guidini MM, Pickup JA, Cookson AR, Vallin H, Wilkinson T, Bazzolli D, Richards J, Wootton M, Mikut R, Hilpert K, Maresca M, Perrier J, Hess M, Mantovani HC, Fernandez-fuentes N, Creevey CJ, Huws SA (2019) In silico identification of novel peptides with antibacterial activity against multidrug-resistant *Staphylococcus aureus*. Access Microbiolo 1(1A)
- Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM (2011) Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS 15:625–636
- Potocnakova L, Bhide M, Pulzova LB (2016) An introduction to B-cell epitope mapping and in silico epitope prediction. J Immunol Res 2016:6760830
- Quereda JJ, Dussurget O, Nahori MA, Ghozlane A, Volant S, Dillies MA, Regnault B, Kennedy S, Mondot S, Villoing B, Cossart P, Pizarro-Cerda J (2016) Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection. PNAS 113(20):5706–5711
- Quereda JJ, Rodriguez-Gomez IM, Meza-Torres J, Carrasco L, Cossart P, Pizarro-Cerda J (2018) Reassessing the role of Internalin B in *Listeria* monocytogenes virulence using the epidemic strain F2365. Clin Microbiol Infect 252:252.e1–252.e4
- Saha S, Raghava G (2006) AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res 34:W202–W209

- Sallami L, Marcotte M, Naim F, Quattara B, Leblanc C, Saucier L (2006) Heat inactivation of *Listeria monocytogenes* and *Salmonella enterica* serovar Typhi in a typical bologna matrix during an industrial cooking-cooling cycle. J Food Prot 69:3025–3030
- Sharma P, Kaur R, Upadhyay AK, Kaushik V (2020) In-Silico prediction of a peptide-based vaccine against Zika virus. Int J Pept Res Ther 26:85–91
- Singh S, Singh H, Tuknait A, Chaudhary K, Singh B, Kumaran S, Raghava GPS (2015) PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues. Biol Direct 10(1):73
- Thomas J, Govender N, McCarthy KM, Erasmus LK, Doyle TJ, Allam M, Jsmail A, Ramalwa N, Sekwadi P, Ntshoe G, Shonhiwa A, Essel V, Tau N, Smouse S, Ngomane HM, Disenyeng B, Page NA, Govender NP, Duse AG, Stewart R, Thomas T, Mahoney D, Tourdjman M, Disson O, Thouvenot P, Maury MM, Leclercq A, Lecuit M, Smith AN, Blumberg LH (2020) Outbreak of Listeriosis in South Africa associated with processed meat. N Engl J Med 382:632–643
- Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461
- Veiga E, Cossart P (2005) Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells. Nat Cell Biol 7:894–900
- Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T (2018) SWISS-MODEL: homology modeling of protein structures and complexes. Nucleic Acids Res 46(W1):W296–W303
- World Health Organization Listeriosis, Australia (2018a) WHO. https ://www.who.int/csr/don/09-april-2018-listeriosis-australia/en/
- World Health Organization. Listeriosis–Spain (2019) Disease outbreak news. Geneva: the Organization. https://www.who.int/csr/don/16september-2019-listeriosis-spain
- World Health Organization South Africa (2018b). https://www.who. int/csr/don/28-march-2018-listeriosis-south-africa/en/
- Yao H, Kang M, Wang Y, Feng Y, Kong S, Cai X, Ling Z, Chen S, Jiao X, Yin Y (2018) An essential role for hfq involved in biofilm formation and virulence in serotype 4b Listeria monocytogenes. Microbiol Res 215:148–154

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.